UBI PHARMA INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14 TWD | +0.36% |
|
+0.72% | -59.60% |
| 18/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,909 | 882.6 | 944.2 | 7,796 | 5,567 | 4,095 |
| Enterprise Value (EV) 1 | 2,388 | 2,674 | 1,731 | 8,268 | 5,686 | 4,255 |
| P/E ratio | -7.92 x | -3.62 x | -12 x | 327 x | 116 x | 5,009 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.5 x | 1.84 x | 1.98 x | 12.1 x | 8.78 x | 6.31 x |
| EV / Revenue | 5.63 x | 5.58 x | 3.63 x | 12.8 x | 8.97 x | 6.56 x |
| EV / EBITDA | -10.7 x | -13.2 x | -15.7 x | 104 x | 75.9 x | 76.2 x |
| EV / FCF | -4.67 x | -3.33 x | 13.7 x | -68.5 x | 204 x | -33.2 x |
| FCF Yield | -21.4% | -30% | 7.31% | -1.46% | 0.49% | -3.01% |
| Price to Book | 2.7 x | 1.73 x | 2.06 x | 8.65 x | 4.98 x | 3.5 x |
| Nbr of stocks (in thousands) | 88,148 | 88,746 | 94,935 | 1,09,464 | 1,15,696 | 1,18,190 |
| Reference price 2 | 21.66 | 9.945 | 9.945 | 71.22 | 48.12 | 34.65 |
| Announcement Date | 25/04/19 | 15/04/20 | 19/04/21 | 29/04/22 | 21/04/23 | 18/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 423.9 | 479.6 | 477.6 | 644.3 | 633.8 | 648.6 |
| EBITDA 1 | -222.3 | -202.1 | -109.9 | 79.33 | 74.9 | 55.86 |
| EBIT 1 | -255.8 | -238.2 | -153.8 | 46.11 | 37.32 | 5.453 |
| Operating Margin | -60.34% | -49.67% | -32.21% | 7.16% | 5.89% | 0.84% |
| Earnings before Tax (EBT) 1 | -249.5 | -255.4 | -90.26 | 23.76 | 54.26 | 2.596 |
| Net income 1 | -241 | -241.9 | -74.22 | 22.36 | 47.21 | 0.803 |
| Net margin | -56.85% | -50.44% | -15.54% | 3.47% | 7.45% | 0.12% |
| EPS 2 | -2.734 | -2.744 | -0.8300 | 0.2180 | 0.4134 | 0.006918 |
| Free Cash Flow 1 | -511.7 | -802.8 | 126.5 | -120.7 | 27.86 | -128.1 |
| FCF margin | -120.72% | -167.41% | 26.5% | -18.73% | 4.4% | -19.74% |
| FCF Conversion (EBITDA) | - | - | - | - | 37.2% | - |
| FCF Conversion (Net income) | - | - | - | - | 59.02% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 25/04/19 | 15/04/20 | 19/04/21 | 29/04/22 | 21/04/23 | 18/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 480 | 1,791 | 787 | 472 | 119 | 160 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.157 x | -8.864 x | -7.16 x | 5.952 x | 1.589 x | 2.865 x |
| Free Cash Flow 1 | -512 | -803 | 127 | -121 | 27.9 | -128 |
| ROE (net income / shareholders' equity) | -29.9% | -41% | -18.6% | 3.29% | 4.68% | 0.07% |
| ROA (Net income/ Total Assets) | -10.8% | -7.01% | -4.55% | 1.68% | 1.23% | 0.18% |
| Assets 1 | 2,227 | 3,450 | 1,633 | 1,335 | 3,824 | 437.4 |
| Book Value Per Share 2 | 8.020 | 5.750 | 4.830 | 8.240 | 9.670 | 9.900 |
| Cash Flow per Share 2 | 2.000 | 0.8200 | 1.480 | 2.730 | 3.420 | 2.880 |
| Capex 1 | 323 | 494 | 109 | 98.2 | 160 | 121 |
| Capex / Sales | 76.3% | 103.04% | 22.82% | 15.24% | 25.28% | 18.63% |
| Announcement Date | 25/04/19 | 15/04/20 | 19/04/21 | 29/04/22 | 21/04/23 | 18/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -59.60% | 51.25M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- 6562 Stock
- Financials UBI Pharma Inc.